J&J's Janssen Gets Health Canada OK for Expanded Imbruvica Use
08 November 2019 - 3:17PM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Friday said it received Health Canada approval of the cancer
drug Imbruvica in combination with obinutuzumab for treatment-naive
patients with active chronic lymphocytic leukemia, or CLL.
Janssen said the indication marks the first approval for a
non-chemotherapy combination regimen for treatment-naive patients
with CLL, one of the most common types of leukemia in adults.
It also marks the ninth indication for Imbruvica in Canada since
its first approval in November 2014, Janssen said.
Imbruvica is commercialized in Canada by Janssen, which jointly
develops the drug with AbbVie Inc.'s (ABBV) Pharmacyclics LLC.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 08, 2019 09:02 ET (14:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024